Cargando…

Changes in the Properties of the Thyrotropin Receptor Antibody in Patients with Graves’ Disease after Radioiodine Treatment

We investigated the effect of a single dose of (131)I upon thyrotropin receptor antibodies (TRAb) in 21 patients with Graves’ disease. The thyrotropin receptor antibodies were assessed by parallel measurements of thyrotropin binding inhibitor immunoglobulin (TBII), thyroid stimulating antibody (TSAb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Bo Youn, Shong, Young Kee, Chung, June-Key, Lee, Myung Chul, Lee, Hong Kyu, Koh, Chang-Soon, Min, Hun Ki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association of Internal Medicine 1990
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534992/ https://www.ncbi.nlm.nih.gov/pubmed/1980206 http://dx.doi.org/10.3904/kjim.1990.5.1.51

Ejemplares similares

Pathogenetic Role of Thyrotropin Receptor Antibody in the Development of Hyperthyroidism Following Primary Hypothyroidism
por: Shong, Young Kee, et al.
Publicado: (1989)

Changes in Thyrotropin Receptor Antibody Levels Following Total Thyroidectomy or Radioiodine Therapy in Patients with Refractory Graves' Disease
por: Kim, Jinyoung, et al.
Publicado: (2021)

Thyrotropin Binding Inhibiting Antibody (TBIAb) in Graves’ Disease
por: Cho, Won Yong, et al.
Publicado: (1988)

Negative correlation between the conversion of thyrotropin receptor-bound blocking type thyrotropin receptor antibody to the stimulating type by anti-human IgG antibodies and the biological activity of blocking type thyrotropin receptor antibody.
por: Cho, B. Y., et al.
Publicado: (1993)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Characteristics of Anti-TSH antibody and Its Relationship with TSH Receptor Antibody(*)
por: Cho, Bo Youn, et al.
Publicado: (1988)

HLA-DR Antigen Expression on the Thyrocytes of Graves’ Disease Patients
por: Lee, Myung Shik, et al.
Publicado: (1988)

Graves' Patient with Thymic Expression of Thyrotropin Receptors and Dynamic Changes in Thymic Hyperplasia Proportional to Graves' Disease Activity
por: Song, Young Shin, et al.
Publicado: (2016)

Changes of Serum Angiotensin-Converting Enzyme Activity During Treatment of Patients with Graves’ Disease(*)
por: Lee, Dong Soo, et al.
Publicado: (1986)

Correction to: Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2021)

Role of Blocking TSH Receptor Antibodies on the Development of Hypothyroidism and Thyroid Atrophy in Primary Myxedema
por: Cho, Bo Youn, et al.
Publicado: (1989)

Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease
por: Kahaly, George J, et al.
Publicado: (2019)

Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves’ Orbitopathy
por: George, Augustine, et al.
Publicado: (2021)

Cut-Off Value of Thyrotropin-Receptor Antibodies in Grave’s Disease in Basrah
por: Radhi, Maher A, et al.
Publicado: (2023)

Overexpression of Both Human Sodium Iodide Symporter (NIS) and BRG1-Bromodomain Synergistically Enhances Radioiodine Sensitivity by Stabilizing p53 through NPM1 Expression
por: Na, Juri, et al.
Publicado: (2023)

Evaluation of the diagnostic performance of thyroid‐stimulating immunoglobulin and thyrotropin receptor antibodies for Graves' disease
por: Xu, Shiji, et al.
Publicado: (2023)

Optimal Thyrotropin Suppression Therapy in Low-Risk Thyroid Cancer Patients after Lobectomy
por: Lee, Yu-Mi, et al.
Publicado: (2019)

Recombinant Human Thyrotropin-Aided Radioiodine Therapy in Patients with Metastatic Differentiated Thyroid Carcinoma
por: Zagar, Ivana, et al.
Publicado: (2012)

Glycosylation of Sodium/Iodide Symporter (NIS) Regulates Its Membrane Translocation and Radioiodine Uptake
por: Chung, Taemoon, et al.
Publicado: (2015)

Post-radioiodine management of patients with Graves' disease
por: Collins, K, et al.
Publicado: (2012)

Radioiodine therapy and Graves’ disease – Myths and reality
por: Plazinska, Maria Teresa, et al.
Publicado: (2020)

Radioiodine Therapy of Graves' Disease and the Uptake Paradox
por: Malapure, Sumeet Suresh, et al.
Publicado: (2020)

Radioiodine Therapy in Differentiated Thyroid Cancer: The First Targeted Therapy in Oncology
por: Chung, June-Key, et al.
Publicado: (2014)

Thyrotropin Receptor Epitope and Human Leukocyte Antigen in Graves’ Disease
por: Inaba, Hidefumi, et al.
Publicado: (2016)

SAT-557 Functional Thyrotropin Receptor Antibodies Confirm a Novel Graves' Disease Animal Model
por: Diana, Tanja, et al.
Publicado: (2019)

Effect of TSH stimulation protocols on adequacy of low-iodine diet for radioiodine administration
por: Lee, Hwanhee, et al.
Publicado: (2021)

Early stimulated thyroglobulin for response prediction after recombinant human thyrotropin-aided radioiodine therapy
por: Park, Hee Jeong, et al.
Publicado: (2017)

Radioiodine Thyroid Ablation in Graves’ Hyperthyroidism: Merits and Pitfalls
por: Nwatsock, J. F., et al.
Publicado: (2012)

The effect of radioiodine treatment on the characteristics of TRAb in Graves’ disease
por: Fang, Ya, et al.
Publicado: (2021)

Clinical Significance of Classification of Graves’ Disease According to the Characteristics of TSH Receptor Antibodies
por: Kim, Won Bae, et al.
Publicado: (2001)

Recombinant Human Thyrotropin-Aided Radioiodine Therapy in Tracheal Obstruction by an Invading Well-Differentiated Thyroid Carcinoma
por: Pontikides, Nickolaos, et al.
Publicado: (2013)

Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
por: Samimi, Hilda, et al.
Publicado: (2022)

Monoclonal Antibodies to the Thyrotropin Receptor
por: Ando, Takao, et al.
Publicado: (2005)

Thyrotropin Receptor Blocking Antibodies
por: Diana, Tanja, et al.
Publicado: (2018)

Radioiodine Therapy-Induced Conversion of Toxic Adenoma to Graves’ Disease
por: Rehman, Anis, et al.
Publicado: (2020)

Should radioiodine now be first line treatment for Graves’ disease?
por: Okosieme, Onyebuchi E., et al.
Publicado: (2020)

Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation
por: Silvestre, Ramona A., et al.
Publicado: (2021)

The Presence of Thyroid-Stimulation Blocking Antibody Prevents High Bone Turnover in Untreated Premenopausal Patients with Graves’ Disease
por: Cho, Sun Wook, et al.
Publicado: (2015)

Localization of In-111 Antimyosin Fab and (99m)Tc-Pyrophosphate in Reperfusion Myocardial Infarction Model
por: Lee, Dong Soo, et al.
Publicado: (1990)

Thyrotropin-producing pituitary adenoma simultaneously existing with Graves’ disease: a case report
por: Arai, Nobuhiko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kscbjsmi0lnd9c7pg6aacl25me